Intellia Therapeutics details progress in Phase 3 trials for NTLA-2002 and nex-z, anticipating key regulatory submissions by 2026. Intellia Therapeutics has announced the initiation of the global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback